Novel factors modulating human β-cell proliferation

Diabetes, Obesity and Metabolism

Volumn 18, Issue , 2016, Pages 71-77

  Shirakawa, J ^a,b   Kulkarni, R N ^a,b,c  

^a JOSLIN DIABETES CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

GNF4877; harmine; human cell proliferation; osteoprotegrin; SerpinB1; WS6

Indexed keywords

5 IODOTUBERCIDIN; BINDING PROTEIN; DENOSUMAB; ERB3 BINDING PROTEIN 1; GLYCOGEN SYNTHASE KINASE 3BETA; HARMINE; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; OSTEOPROTEGERIN; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR B1; SMAD2 PROTEIN; TRANSCRIPTION FACTOR PDX 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WS 6; (1H-INDOL-5-YL)PROPAN-2-AMINE; CARBANILAMIDE DERIVATIVE; DYRK KINASE; MONOAMINE OXIDASE INHIBITOR; PA2G4 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RNA BINDING PROTEIN; SERPINB1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRYPTAMINE DERIVATIVE; WS6 COMPOUND;

CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; NONHUMAN; NUCLEAR REPROGRAMMING; PANCREAS ISLET BETA CELL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DIABETES MELLITUS; DRUG EFFECTS; METABOLISM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL PROLIFERATION; DENOSUMAB; DIABETES MELLITUS; GLYCOGEN SYNTHASE KINASE 3 BETA; HARMINE; HUMANS; I-KAPPA B KINASE; INSULIN-SECRETING CELLS; MONOAMINE OXIDASE INHIBITORS; OSTEOPROTEGERIN; PHENYLUREA COMPOUNDS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA-BINDING PROTEINS; SERINE PROTEINASE INHIBITORS; SERPINS; TRYPTAMINES;

EID: 84987811470     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12731     Document Type: Review

References (78)

1. Kulkarni RN, Mizrachi EB, Ocana AG, Stewart AF. Human beta-cell proliferation and intracellular signaling: driving in the dark without a road map. Diabetes. 2012;61:2205–2213.
2. Bernal-Mizrachi E, Kulkarni RN, Scott DK, Mauvais-Jarvis F, Stewart AF, Garcia-Ocana A. Human beta-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map. Diabetes. 2014;63:819–831.
3. Stewart AF, Hussain MA, Garcia-Ocana A, et al. Human beta-cell proliferation and intracellular signaling: part 3. Diabetes. 2015;64:1872–1885.
4. Wang P, Fiaschi-Taesch NM, Vasavada RC, Scott DK, Garcia-Ocana A, Stewart AF. Diabetes mellitus--advances and challenges in human beta-cell proliferation. Nat Rev Endocrinol. 2015;11:201–212.
5. Kulkarni RN, Stewart AF. Summary of the Keystone islet workshop (April 2014): the increasing demand for human islet availability in diabetes research. Diabetes. 2014;63:3979–3981.
6. Chakradhar S. Diabetes researchers fear worsening access to human islets. Nat Med. 2014;20:567.
7. Walpita D, Hasaka T, Spoonamore J, et al. A human islet cell culture system for high-throughput screening. J Biomol Screen. 2012;17:509–518.
8. Wang W, Walker JR, Wang X, et al. Identification of small-molecule inducers of pancreatic beta-cell expansion. Proc Natl Acad Sci USA. 2009;106:1427–1432.
9. Annes JP, Ryu JH, Lam K, et al. Adenosine kinase inhibition selectively promotes rodent and porcine islet beta-cell replication. Proc Natl Acad Sci USA. 2012;109:3915–3920.
10. Shen W, Tremblay MS, Deshmukh VA, et al. Small-molecule inducer of beta cell proliferation identified by high-throughput screening. J Am Chem Soc. 2013;135:1669–1672.
11. Wang P, Alvarez-Perez JC, Felsenfeld DP, et al. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat Med. 2015;21:383–388.
12. Shen W, Taylor B, Jin Q, et al. Inhibition of DYRK1A and GSK3B induces human beta-cell proliferation. Nat Commun. 2015;6:8372.
13. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IkappaB kinase. Cell. 1997;90:373–383.
14. Dirice E, Kahraman S, Jiang W, et al. Soluble factors secreted by T cells promote beta-cell proliferation. Diabetes. 2014;63:188–202.
15. Radomski N, Jost E. Molecular cloning of a murine cDNA encoding a novel protein, p38-2G4, which varies with the cell cycle. Exp Cell Res. 1995;220:434–445.
16. Zhang Y, Woodford N, Xia X, Hamburger AW. Repression of E2F1-mediated transcription by the ErbB3 binding protein Ebp1 involves histone deacetylases. Nucleic Acids Res. 2003;31:2168–2177.
17. Fajas L, Annicotte JS, Miard S, Sarruf D, Watanabe M, Auwerx J. Impaired pancreatic growth, beta cell mass, and beta cell function in E2F1 (-/-) mice. J Clin Invest. 2004;113:1288–1295.
18. Boerner BP, George NM, Mir SU, Sarvetnick NE. WS6 induces both alpha and beta cell proliferation without affecting differentiation or viability. Endocr J. 2015;62:379–386.
19. Dirice E, Walpita D, Vetere A, et al. Inhibition of DYRK1A stimulates human beta-cell proliferation. Diabetes. 2016;65:1660–1671.
20. Arron JR, Winslow MM, Polleri A, et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature. 2006;441:595–600.
21. Gwack Y, Sharma S, Nardone J, et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature. 2006;441:646–650.
22. Heit JJ, Apelqvist AA, Gu X, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature. 2006;443:345–349.
23. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 1998;391:900–904.
24. Demozay D, Tsunekawa S, Briaud I, Shah R, Rhodes CJ. Specific glucose-induced control of insulin receptor substrate-2 expression is mediated via Ca2+-dependent calcineurin/NFAT signaling in primary pancreatic islet beta-cells. Diabetes. 2011;60:2892–2902.
25. Goodyer WR, Gu X, Liu Y, Bottino R, Crabtree GR, Kim SK. Neonatal beta cell development in mice and humans is regulated by calcineurin/NFAT. Dev Cell. 2012;23:21–34.
26. Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab. 2006;32:539–546.
27. Rachdi L, Kariyawasam D, Guez F, et al. Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass. Diabetologia. 2014;57:960–969.
28. Rachdi L, Kariyawasam D, Aiello V, et al. Dyrk1A induces pancreatic beta cell mass expansion and improves glucose tolerance. Cell Cycle. 2014;13:2221–2229.
29. Reniers J, Robert S, Frederick R, Masereel B, Vincent S, Wouters J. Synthesis and evaluation of beta-carboline derivatives as potential monoamine oxidase inhibitors. Bioorg Med Chem. 2011;19:134–144.
30. Drung B, Scholz C, Barbosa VA, Nazari A, Sarragiotto MH, Schmidt B. Computational & experimental evaluation of the structure/activity relationship of beta-carbolines as DYRK1A inhibitors. Bioorg Med Chem Lett. 2014;24:4854–4860.
31. Abbassi R, Johns TG, Kassiou M, Munoz L. DYRK1A in neurodegeneration and cancer: molecular basis and clinical implications. Pharmacol Ther. 2015;151:87–98.
32. Waki H, Park KW, Mitro N, et al. The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. Cell Metab. 2007;5:357–370.
33. Nakagawa Y, Suzuki T, Ishii H, Ogata A, Nakae D. Mitochondrial dysfunction and biotransformation of beta-carboline alkaloids, harmine and harmaline, on isolated rat hepatocytes. Chem Biol Interact. 2010;188:393–403.
34. Khor B, Gagnon JD, Goel G et al. The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells. eLife. 2015;4:e05920.
35. Kondoh D, Yamamoto S, Tomita T, et al. Harmine lengthens circadian period of the mammalian molecular clock in the suprachiasmatic nucleus. Biol Pharm Bull. 2014;37:1422–1427.
36. Berg S, Bergh M, Hellberg S, et al. Discovery of novel potent and highly selective glycogen synthase kinase-3beta (GSK3beta) inhibitors for Alzheimer's disease: design, synthesis, and characterization of pyrazines. J Med Chem. 2012;55:9107–9119.
37. Liu Y, Tanabe K, Baronnier D, et al. Conditional ablation of Gsk-3beta in islet beta cells results in expanded mass and resistance to fat feeding-induced diabetes in mice. Diabetologia. 2010;53:2600–2610.
38. Liu Z, Tanabe K, Bernal-Mizrachi E, Permutt MA. Mice with beta cell overexpression of glycogen synthase kinase-3beta have reduced beta cell mass and proliferation. Diabetologia. 2008;51:623–631.
39. Shirakawa J, Togashi Y, Sakamoto E, et al. Glucokinase activation ameliorates ER stress-induced apoptosis in pancreatic beta-cells. Diabetes. 2013;62:3448–3458.
40. Srinivasan S, Ohsugi M, Liu Z, Fatrai S, Bernal-Mizrachi E, Permutt MA. Endoplasmic reticulum stress-induced apoptosis is partly mediated by reduced insulin signaling through phosphatidylinositol 3-kinase/Akt and increased glycogen synthase kinase-3beta in mouse insulinoma cells. Diabetes. 2005;54:968–975.
41. Tanabe K, Liu Z, Patel S, et al. Genetic deficiency of glycogen synthase kinase-3beta corrects diabetes in mouse models of insulin resistance. PLoS Biol. 2008;6:e37.
42. Liu H, Remedi MS, Pappan KL, et al. Glycogen synthase kinase-3 and mammalian target of rapamycin pathways contribute to DNA synthesis, cell cycle progression, and proliferation in human islets. Diabetes. 2009;58:663–672.
43. Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science. 1997;275:1930–1934.
44. Rieck S, Kaestner KH. Expansion of beta-cell mass in response to pregnancy. Trends Endocrinol Metab. 2010;21:151–158.
45. Zhang H, Zhang J, Pope CF, et al. Gestational diabetes mellitus resulting from impaired beta-cell compensation in the absence of FoxM1, a novel downstream effector of placental lactogen. Diabetes. 2010;59:143–152.
46. Demirci C, Ernst S, Alvarez-Perez JC, et al. Loss of HGF/c-Met signaling in pancreatic beta-cells leads to incomplete maternal beta-cell adaptation and gestational diabetes mellitus. Diabetes. 2012;61:1143–1152.
47. Karnik SK, Chen H, McLean GW, et al. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science. 2007;318:806–809.
48. Kim H, Toyofuku Y, Lynn FC, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med. 2010;16:804–808.
49. Chen H, Kleinberger JW, Takane KK, et al. Augmented Stat5 signaling bypasses multiple impediments to lactogen-mediated proliferation in human beta-cells. Diabetes. 2015;64:3784–3797.
50. Rieck S, White P, Schug J, et al. The transcriptional response of the islet to pregnancy in mice. Mol Endocrinol. 2009;23:1702–1712.
51. Schrader J, Rennekamp W, Niebergall U, et al. Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death. Diabetologia. 2007;50:1243–1247.
52. Kondegowda NG, Fenutria R, Pollack IR, et al. Osteoprotegerin and denosumab stimulate human beta cell proliferation through inhibition of the receptor activator of NF-kappaB ligand pathway. Cell Metab. 2015;22:77–85.
53. Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front Immunol. 2014;5:511.
54. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–831.
55. Terauchi Y, Takamoto I, Kubota N, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest. 2007;117:246–257.
56. Song WJ, Schreiber WE, Zhong E, et al. Exendin-4 stimulation of cyclin A2 in beta-cell proliferation. Diabetes. 2008;57:2371–2381.
57. Mezza T, Muscogiuri G, Sorice GP, et al. Insulin resistance alters islet morphology in nondiabetic humans. Diabetes. 2014;63:994–1007.
58. Montanya E. Insulin resistance compensation: not just a matter of beta-cells? Diabetes. 2014;63:832–834.
59. El Ouaamari A, Zhou JY, Liew CW, et al. Compensatory islet response to insulin resistance revealed by quantitative proteomics. J Proteome Res. 2015;14:3111–3122.
60. Araki E, Lipes MA, Patti ME, et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature. 1994;372:186–190.
61. Flier SN, Kulkarni RN, Kahn CR. Evidence for a circulating islet cell growth factor in insulin-resistant states. Proc Natl Acad Sci USA. 2001;98:7475–7480.
62. Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6:87–97.
63. El Ouaamari A, Kawamori D, Dirice E, et al. Liver-derived systemic factors drive beta cell hyperplasia in insulin-resistant states. Cell Rep. 2013;3:401–410.
64. Salpeter SJ, Khalaileh A, Weinberg-Corem N, Ziv O, Glaser B, Dor Y. Systemic regulation of the age-related decline of pancreatic beta-cell replication. Diabetes. 2013;62:2843–2848.
65. El Ouaamari A, Dirice E, Gedeon N, et al. SerpinB1 promotes pancreatic beta cell proliferation. Cell Metab. 2016;23:194–205.
66. Aikawa N, Kawasaki Y. Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome. Ther Clin Risk Manag. 2014;10:621–629.
67. Boerner BP, George NM, Targy NM, Sarvetnick NE. TGF-beta superfamily member Nodal stimulates human beta-cell proliferation while maintaining cellular viability. Endocrinology. 2013;154:4099–4112.
68. Dhawan S, Dirice E, Kulkarni RN, Bhushan A. Inhibition of TGF-beta signaling promotes human pancreatic beta cell replication. Diabetes. 2016;65:1208–1218.
69. Purwana I, Zheng J, Li X, et al. GABA promotes human beta-cell proliferation and modulates glucose homeostasis. Diabetes. 2014;63:4197–4205.
70. Kassem S, Bhandari S, Rodriguez-Bada P, et al. Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl J Med. 2010;362:1348–1350.
71. Stamateris RE, Sharma RB, Kong Y, et al. Glucose induces mouse beta cell proliferation via IRS2, mTOR and cyclin D2 but not the insulin receptor. Diabetes. 2016;65:981–995.
72. Tornovsky-Babeay S, Dadon D, Ziv O, et al. Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in beta cells. Cell Metab. 2014;19:109–121.
73. Grapensparr L, Vasylovska S, Li Z, et al. Co-transplantation of human pancreatic islets with post-migratory neural crest stem cells increases beta-cell proliferation and vascular and neural regrowth. J Clin Endocrinol Metab. 2015;100:E583–E590.
74. Takebe T, Enomura M, Yoshizawa E, et al. Vascularized and complex organ buds from diverse tissues via mesenchymal cell-driven condensation. Cell Stem Cell. 2015;16:556–565.
75. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell. 2012;150:1223–1234.
76. Cinti F, Bouchi R, Kim-Muller JY, et al. Evidence of beta-cell dedifferentiation in human type 2 diabetes. J Clin Endocrinol Metab. 2016;101:1044–1054.
77. Talchai C, Xuan S, Kitamura T, DePinho RA, Accili D. Generation of functional insulin-producing cells in the gut by Foxo1 ablation. Nat Genet. 2012;44:406–412, S401.
78. Ariyachet C, Tovaglieri A, Xiang G, et al. Reprogrammed stomach tissue as a renewable source of functional beta cells for blood glucose regulation. Cell Stem Cell. 2016;18:410–421.